Skip to main content
Erschienen in: Annals of Surgical Oncology 1/2009

01.01.2009 | Thoracic Oncology

Impact of Teaching Facility Status and High-Volume Centers on Outcomes for Lung Cancer Resection: An Examination of 13,469 Surgical Patients

verfasst von: Michael C. Cheung, MD, Kara Hamilton, MS, Recinda Sherman, BS, Margaret M. Byrne, PhD, Dao M. Nguyen, MD, Dido Franceschi, MD, Leonidas G. Koniaris, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 1/2009

Einloggen, um Zugang zu erhalten

Abstract

Background

Studies suggest that institutional case volume and teaching status significantly affect patient survival. We sought to compare outcomes of surgical resection for lung cancer at teaching facilities (TF) and at high-volume centers (HVC).

Methods

Patients undergoing lung cancer resection with curative intent were examined using a linked dataset from 1998 to 2002 between the Florida Cancer Data System and the Florida Agency for Health Care Administration.

Results

A total of 13,469 patients were analyzed and outcomes adjusted for comorbidities. Median survival time (MST) was superior for patients treated at TF versus nonteaching facilities (NTF) (47.1 versus 40.5 months, P < 0.001). Mortality rates at NTF were higher at 30 days (2.6% versus 1.1%, P < 0.001), 90 days (6.8% versus 3.8%, P < 0.001), and at 5 years (63.9% versus 59.2%, P = 0.005). Similarly, MST was superior in the cohort treated at HVC versus low-volume center (LVC) (45.1 versus 39.8 months, P < 0.001). Mortality was observed to be higher in LVC than HVC at 30 days (2.7% versus 1.6%, P < 0.001), 90 days (7.5% versus 4.0%, P < 0.001), and at 5 years (63.5% versus 59.3%, P = 0.002). Significant preoperative, independent predictors of survival include age, sex, smoking status, and the existence of certain comorbidities. Treatment at a TF or HVC were independent predictors of better outcome. Race, use of chemotherapy or radiation did not affect outcomes.

Conclusion

Surgical treatment for lung cancer at TF or HVC results in significantly better short- and long-term patient outcomes.
Literatur
1.
Zurück zum Zitat Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007; 57:43–66CrossRefPubMed Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007; 57:43–66CrossRefPubMed
2.
Zurück zum Zitat Gkiozos I, Charpidou A, Syrigos K. Developments in the treatment of non-small cell lung cancer. Anticancer Res 2007; 27:2823–7PubMed Gkiozos I, Charpidou A, Syrigos K. Developments in the treatment of non-small cell lung cancer. Anticancer Res 2007; 27:2823–7PubMed
4.
Zurück zum Zitat Luft HS, Bunker JP, Enthoven AC. Should operations be regionalized? The empirical relation between surgical volume and mortality. N Engl J Med 1979; 301:1364–9CrossRefPubMed Luft HS, Bunker JP, Enthoven AC. Should operations be regionalized? The empirical relation between surgical volume and mortality. N Engl J Med 1979; 301:1364–9CrossRefPubMed
5.
Zurück zum Zitat Luft HS. The relation between surgical volume and mortality: an exploration of causal factors and alternative models. Med Care 1980; 18:940–59CrossRefPubMed Luft HS. The relation between surgical volume and mortality: an exploration of causal factors and alternative models. Med Care 1980; 18:940–59CrossRefPubMed
6.
Zurück zum Zitat Begg CB, Cramer LD, Hoskins WJ, et al Impact of hospital volume on operative mortality for major cancer surgery. JAMA 1998; 280:1747–51CrossRefPubMed Begg CB, Cramer LD, Hoskins WJ, et al Impact of hospital volume on operative mortality for major cancer surgery. JAMA 1998; 280:1747–51CrossRefPubMed
8.
Zurück zum Zitat Gutierrez JC, Perez EA, Franceschi D, et al. Outcomes for soft-tissue sarcoma in 8249 cases from a large state cancer registry. J Surg Res 2007; 141:105–14CrossRefPubMed Gutierrez JC, Perez EA, Franceschi D, et al. Outcomes for soft-tissue sarcoma in 8249 cases from a large state cancer registry. J Surg Res 2007; 141:105–14CrossRefPubMed
9.
Zurück zum Zitat Bach PB, Cramer LD, Schrag D, et al. The influence of hospital volume on survival after resection for lung cancer. N Engl J Med 2001; 345:181–8CrossRefPubMed Bach PB, Cramer LD, Schrag D, et al. The influence of hospital volume on survival after resection for lung cancer. N Engl J Med 2001; 345:181–8CrossRefPubMed
10.
Zurück zum Zitat Hannan EL, Radzyner M, Rubin D, et al. The influence of hospital and surgeon volume on in-hospital mortality for colectomy, gastrectomy, and lung lobectomy in patients with cancer. Surgery 2002; 131:6–15CrossRefPubMed Hannan EL, Radzyner M, Rubin D, et al. The influence of hospital and surgeon volume on in-hospital mortality for colectomy, gastrectomy, and lung lobectomy in patients with cancer. Surgery 2002; 131:6–15CrossRefPubMed
11.
Zurück zum Zitat Gutierrez JC, Perez EA, Moffat FL, et al. Should soft tissue sarcomas be treated at high-volume centers? An analysis of 4205 patients. Ann Surg 2007; 245:952–8CrossRefPubMedPubMedCentral Gutierrez JC, Perez EA, Moffat FL, et al. Should soft tissue sarcomas be treated at high-volume centers? An analysis of 4205 patients. Ann Surg 2007; 245:952–8CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Khuri SF, Najjar SF, Daley J, et al. Comparison of surgical outcomes between teaching and nonteaching hospitals in the Department of Veterans Affairs. Ann Surg 2001; 234:370–82; discussion 382–3CrossRefPubMedPubMedCentral Khuri SF, Najjar SF, Daley J, et al. Comparison of surgical outcomes between teaching and nonteaching hospitals in the Department of Veterans Affairs. Ann Surg 2001; 234:370–82; discussion 382–3CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Knipp BS, Deeb GM, Prager RL, et al. A contemporary analysis of outcomes for operative repair of type A aortic dissection in the United States. Surgery 2007; 142:524–8CrossRefPubMed Knipp BS, Deeb GM, Prager RL, et al. A contemporary analysis of outcomes for operative repair of type A aortic dissection in the United States. Surgery 2007; 142:524–8CrossRefPubMed
14.
Zurück zum Zitat Colice GL, Shafazand S, Griffin JP, et al. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest 2007; 132:161–77SCrossRef Colice GL, Shafazand S, Griffin JP, et al. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest 2007; 132:161–77SCrossRef
15.
Zurück zum Zitat Meguid RA, Brooke BS, Chang DC, et al. Are surgical outcomes for lung cancer resections improved at teaching hospitals? Ann Thorac Surg 2008; 85:1015–24; discussion 1024–5CrossRefPubMed Meguid RA, Brooke BS, Chang DC, et al. Are surgical outcomes for lung cancer resections improved at teaching hospitals? Ann Thorac Surg 2008; 85:1015–24; discussion 1024–5CrossRefPubMed
16.
Zurück zum Zitat Romano PS, Mark DH. Patient and hospital characteristics related to in-hospital mortality after lung cancer resection. Chest 1992; 101:1332–7CrossRefPubMed Romano PS, Mark DH. Patient and hospital characteristics related to in-hospital mortality after lung cancer resection. Chest 1992; 101:1332–7CrossRefPubMed
17.
Zurück zum Zitat Schroen AT, Cress RD. Use of surgical procedures and adjuvant therapy in rectal cancer treatment: a population-based study. Ann Surg 2001; 234:641–51CrossRefPubMedPubMedCentral Schroen AT, Cress RD. Use of surgical procedures and adjuvant therapy in rectal cancer treatment: a population-based study. Ann Surg 2001; 234:641–51CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Freixinet JL, Julia-Serda G, Rodriguez PM, et al. Hospital volume: operative morbidity, mortality and survival in thoracotomy for lung cancer. A Spanish multicenter study of 2994 cases. Eur J Cardiothorac Surg 2006; 29:20–5CrossRefPubMed Freixinet JL, Julia-Serda G, Rodriguez PM, et al. Hospital volume: operative morbidity, mortality and survival in thoracotomy for lung cancer. A Spanish multicenter study of 2994 cases. Eur J Cardiothorac Surg 2006; 29:20–5CrossRefPubMed
19.
Zurück zum Zitat Keagy BA, Lores ME, Starek PJ, et al. Elective pulmonary lobectomy: factors associated with morbidity and operative mortality. Ann Thorac Surg 1985; 40:349–52CrossRefPubMed Keagy BA, Lores ME, Starek PJ, et al. Elective pulmonary lobectomy: factors associated with morbidity and operative mortality. Ann Thorac Surg 1985; 40:349–52CrossRefPubMed
20.
Zurück zum Zitat Nagasaki F, Flehinger BJ, Martini N. Complications of surgery in the treatment of carcinoma of the lung. Chest 1982; 82:25–9CrossRefPubMed Nagasaki F, Flehinger BJ, Martini N. Complications of surgery in the treatment of carcinoma of the lung. Chest 1982; 82:25–9CrossRefPubMed
21.
Zurück zum Zitat Wahi R, McMurtrey MJ, DeCaro LF, et al. Determinants of perioperative morbidity and mortality after pneumonectomy. Ann Thorac Surg 1989; 48:33–7CrossRefPubMed Wahi R, McMurtrey MJ, DeCaro LF, et al. Determinants of perioperative morbidity and mortality after pneumonectomy. Ann Thorac Surg 1989; 48:33–7CrossRefPubMed
22.
Zurück zum Zitat BTS guidelines: guidelines on the selection of patients with lung cancer for surgery. Thorax 2001; 56:89–108 BTS guidelines: guidelines on the selection of patients with lung cancer for surgery. Thorax 2001; 56:89–108
23.
Zurück zum Zitat Beckles MA, Spiro SG, Colice GL, et al. The physiologic evaluation of patients with lung cancer being considered for resectional surgery. Chest 2003; 123:105–14SCrossRef Beckles MA, Spiro SG, Colice GL, et al. The physiologic evaluation of patients with lung cancer being considered for resectional surgery. Chest 2003; 123:105–14SCrossRef
24.
Zurück zum Zitat Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350:351–60CrossRefPubMed Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350:351–60CrossRefPubMed
25.
Zurück zum Zitat Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006; 7:719–27CrossRefPubMed Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006; 7:719–27CrossRefPubMed
26.
Zurück zum Zitat Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 2004; 350:1713–21CrossRefPubMed Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 2004; 350:1713–21CrossRefPubMed
27.
Zurück zum Zitat Scagliotti GV, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst 2003; 95:1453–61CrossRefPubMed Scagliotti GV, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst 2003; 95:1453–61CrossRefPubMed
28.
Zurück zum Zitat Strauss GMHJE, Maddaus MA, Johnstone DW, et al. Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): update of cancer and leukemia group B (CALGB) protocol 9633. J Clin Oncol, 2006; ASCO Annual Meeting Proceedings Part I 2006; 24(No. 18S) Strauss GMHJE, Maddaus MA, Johnstone DW, et al. Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): update of cancer and leukemia group B (CALGB) protocol 9633. J Clin Oncol, 2006; ASCO Annual Meeting Proceedings Part I 2006; 24(No. 18S)
29.
Zurück zum Zitat Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005; 352:2589–97CrossRefPubMed Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005; 352:2589–97CrossRefPubMed
30.
Zurück zum Zitat Brahmer JR, Ettinger DS. Non-small cell lung cancer: adjuvant and neo-adjuvant chemotherapy. Respirology 2007; 12:320–5CrossRefPubMed Brahmer JR, Ettinger DS. Non-small cell lung cancer: adjuvant and neo-adjuvant chemotherapy. Respirology 2007; 12:320–5CrossRefPubMed
32.
Zurück zum Zitat Pignon JP, Tribodet H, Scagliotti GV, et al. Lung Adjuvant Cisplatin Evaluation (LACE): a pooled analysis of five randomized clinical trials including 4,584 patients. J Clin Oncol, 2006; ASCO Annual Meeting Proceedings Part I 2006; 24(No. 18S):7008 Pignon JP, Tribodet H, Scagliotti GV, et al. Lung Adjuvant Cisplatin Evaluation (LACE): a pooled analysis of five randomized clinical trials including 4,584 patients. J Clin Oncol, 2006; ASCO Annual Meeting Proceedings Part I 2006; 24(No. 18S):7008
33.
Zurück zum Zitat Gutierrez JC, Kassira N, Salloum RM, et al. Surgery for rectal cancer performed at teaching hospitals improves survival and preserves continence. J Gastrointest Surg 2007; 11:1441–8; discussion 1448–50CrossRefPubMed Gutierrez JC, Kassira N, Salloum RM, et al. Surgery for rectal cancer performed at teaching hospitals improves survival and preserves continence. J Gastrointest Surg 2007; 11:1441–8; discussion 1448–50CrossRefPubMed
34.
Zurück zum Zitat Perez EA, Gutierrez JC, Jin X, et al. Surgical outcomes of gastrointestinal sarcoma including gastrointestinal stromal tumors: a population-based examination. J Gastrointest Surg 2007; 11:114–25CrossRefPubMed Perez EA, Gutierrez JC, Jin X, et al. Surgical outcomes of gastrointestinal sarcoma including gastrointestinal stromal tumors: a population-based examination. J Gastrointest Surg 2007; 11:114–25CrossRefPubMed
35.
Zurück zum Zitat Perez EA, Livingstone AS, Franceschi D, et al. Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors. J Am Coll Surg 2006; 202:623–9CrossRefPubMed Perez EA, Livingstone AS, Franceschi D, et al. Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors. J Am Coll Surg 2006; 202:623–9CrossRefPubMed
36.
Zurück zum Zitat Hodgson N, Koniaris LG, Livingstone AS, et al. Gastric carcinoids: a temporal increase with proton pump introduction. Surg Endosc 2005; 19:1610–2CrossRefPubMed Hodgson N, Koniaris LG, Livingstone AS, et al. Gastric carcinoids: a temporal increase with proton pump introduction. Surg Endosc 2005; 19:1610–2CrossRefPubMed
37.
Zurück zum Zitat Perez EA, Koniaris LG, Snell SE, et al. 7201 carcinoids: increasing incidence overall and disproportionate mortality in the elderly. World J Surg 2007; 31:1022–30CrossRefPubMed Perez EA, Koniaris LG, Snell SE, et al. 7201 carcinoids: increasing incidence overall and disproportionate mortality in the elderly. World J Surg 2007; 31:1022–30CrossRefPubMed
38.
Zurück zum Zitat Chen CS, Liu TC, Lin HC, et al. Does high surgeon and hospital surgical volume raise the five-year survival rate for breast cancer? A population-based study. Breast Cancer Res Treat 2008; 110(2):349–56CrossRefPubMed Chen CS, Liu TC, Lin HC, et al. Does high surgeon and hospital surgical volume raise the five-year survival rate for breast cancer? A population-based study. Breast Cancer Res Treat 2008; 110(2):349–56CrossRefPubMed
39.
Zurück zum Zitat Lin CC, Lin HC. Effects of surgeon and hospital volume on 5-year survival rates following oral cancer resections: the experience of an Asian country. Surgery 2008; 143:343–51CrossRefPubMed Lin CC, Lin HC. Effects of surgeon and hospital volume on 5-year survival rates following oral cancer resections: the experience of an Asian country. Surgery 2008; 143:343–51CrossRefPubMed
40.
Zurück zum Zitat McKay A, You I, Bigam D, et al. Impact of surgeon training on outcomes after resective hepatic surgery. Ann Surg Oncol 2008 McKay A, You I, Bigam D, et al. Impact of surgeon training on outcomes after resective hepatic surgery. Ann Surg Oncol 2008
41.
Zurück zum Zitat Wen HC, Tang CH, Lin HC, et al. Association between surgeon and hospital volume in coronary artery bypass graft surgery outcomes: a population-based study. Ann Thorac Surg 2006; 81:835–42CrossRefPubMed Wen HC, Tang CH, Lin HC, et al. Association between surgeon and hospital volume in coronary artery bypass graft surgery outcomes: a population-based study. Ann Thorac Surg 2006; 81:835–42CrossRefPubMed
42.
Zurück zum Zitat Xirasagar S, Lien YC, Lin HC, et al. Procedure volume of gastric cancer resections versus 5-year survival. Eur J Surg Oncol 2008; 34:23–9CrossRefPubMed Xirasagar S, Lien YC, Lin HC, et al. Procedure volume of gastric cancer resections versus 5-year survival. Eur J Surg Oncol 2008; 34:23–9CrossRefPubMed
Metadaten
Titel
Impact of Teaching Facility Status and High-Volume Centers on Outcomes for Lung Cancer Resection: An Examination of 13,469 Surgical Patients
verfasst von
Michael C. Cheung, MD
Kara Hamilton, MS
Recinda Sherman, BS
Margaret M. Byrne, PhD
Dao M. Nguyen, MD
Dido Franceschi, MD
Leonidas G. Koniaris, MD
Publikationsdatum
01.01.2009
Verlag
Springer New York
Erschienen in
Annals of Surgical Oncology / Ausgabe 1/2009
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-008-0025-9

Weitere Artikel der Ausgabe 1/2009

Annals of Surgical Oncology 1/2009 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.